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Introduction {#sec001}
============

Thyroid hormones (THs), thyroxine (T4) and 3,5,3'-triiodothyronine (T3), play an essential role in brain development and function \[[@pone.0236113.ref001]\]. Although the thyroid gland synthesizes mainly T4, most actions of THs are mediated by binding of the transcriptionally active form, T3, to its nuclear receptors regulating gene expression patterns \[[@pone.0236113.ref002]\]. In addition to genomic actions, both T3 and T4 can also exert non-genomic actions through receptors in the plasma membrane, cytoplasm or mitochondria \[[@pone.0236113.ref003]\].

In the brain, T4 is the primary source of T3 \[[@pone.0236113.ref004], [@pone.0236113.ref005]\]. T4 crosses the brain barriers (BBs, including the blood--brain barrier, BBB, and the blood--cerebrospinal fluid barrier) through TH transporters into the astrocytes where it is converted to T3 by the action of the selenoenzyme deiodinase type II (DIO2) \[[@pone.0236113.ref006]\]. Although to a lesser extent, T3 can also be transported across the BBs directly into the extracellular fluid where it accesses the target neural cells \[[@pone.0236113.ref007]\]. Regarding TH transport across cellular membranes, among all the membrane proteins that can transport THs, the monocarboxylate transporter 8 (MCT8 \[[@pone.0236113.ref008]\]) and the organic anion transporter family member 1C1 (OATP1C1 \[[@pone.0236113.ref009]\]) are critical for the transport of THs across the BBs \[[@pone.0236113.ref010]\]. MCT8 shows high specificity for both T4 and T3 transport whereas OATP1C1 presents higher selectivity for T4. There are important differences between mice and humans regarding the expression of these transporter proteins in the brain. In both mice and humans, MCT8 is abundantly present in the endothelial cells of the BBB. In contrast, OATP1C1 is abundantly expressed in the mice BBB but is only present at very low levels in humans \[[@pone.0236113.ref011]--[@pone.0236113.ref014]\].

Inactivating mutations in the gene encoding for the MCT8 (*SLC16A2*) transporter located on the X chromosome \[[@pone.0236113.ref015]\] result in MCT8 deficiency, also known as the Allan--Herndon--Dudley syndrome, in males \[[@pone.0236113.ref016], [@pone.0236113.ref017]\]. Patients present abnormal TH concentrations in the serum with elevated T3 (leading to peripheral hyperthyroidism), low T4 and reverse T3 and normal or slightly elevated thyrotropin (TSH) \[[@pone.0236113.ref016]--[@pone.0236113.ref019]\]. Patients also suffer from severe neurological manifestations including global developmental delay, intellectual disability, lack of speech and motor impairments (central hypotonia with poor head control, progressive spastic quadriplegia and dystonic movements; \[[@pone.0236113.ref020], [@pone.0236113.ref021]\]). These alterations appear as a consequence of brain hypothyroidism \[[@pone.0236113.ref022]--[@pone.0236113.ref024]\], most probably caused by the lack of a functional MCT8 in the BBs impairing THs transport across the BBs to the brain \[[@pone.0236113.ref025]--[@pone.0236113.ref027]\].

Despite efforts to develop an effective therapeutic strategy \[[@pone.0236113.ref028]\], the treatments available so far have only been successful in ameliorating the peripheral hyperthyroidism \[[@pone.0236113.ref018], [@pone.0236113.ref029]--[@pone.0236113.ref031]\] but have failed to improve the neurological impairments. Since available evidence suggests that brain hypothyroidism in MCT8 deficiency arises from impaired TH transport across the BBs, the use of delivery pathways that bypass the BBs may offer opportunities for the treatment of the neurological defects of MCT8-deficient patients.

The nasal cavity provides a direct pathway to the brain that can be used to deliver therapeutic agents by intranasal administration bypassing the BBs widely demonstrated in preclinical and clinical studies \[[@pone.0236113.ref032], [@pone.0236113.ref033]\]. The intranasal delivery approach was developed by Frey \[[@pone.0236113.ref034]\], and it provides a non-invasive drug administration route that bypasses the BBs while reducing systemic exposure and therefore side effects \[[@pone.0236113.ref032]\]. Drugs administered in the nasal cavity can be transported directly to the brain along the olfactory \[[@pone.0236113.ref035]\] and trigeminal nerves \[[@pone.0236113.ref036], [@pone.0236113.ref037]\] as these neural pathways connect the nasal mucosa to the brain. This transport can take place through two different pathways. Using the intracellular pathway, drugs are internalized into vesicles by endocytosis in olfactory sensory neurons, they are then anterogradely transported along axons to the neuron's projection site where they are finally released by exocytosis \[[@pone.0236113.ref038]\]. In the extracellular pathway, drugs cross the nasal epithelium by paracellular transport, then travel along the perineural space until they reach the subarachnoid space of the brain \[[@pone.0236113.ref039]\] from which they rapidly travel to other brain regions via the perivascular spaces of the cerebrovasculature \[[@pone.0236113.ref040]\]. This delivery route has been successfully used to rapidly deliver and target insulin to the brain to improve memory in normal healthy adults \[[@pone.0236113.ref041]\] and in patients with Alzheimer's disease \[[@pone.0236113.ref042], [@pone.0236113.ref043]\] without altering the blood levels of insulin or glucose. Intranasal deferoxamine (656.8 g/mol), a high affinity iron chelator of a similar molecular size as T3 (650.97 g/mol), has been reported to target the brain to treat animal models of stroke \[[@pone.0236113.ref044]\], Alzheimer's \[[@pone.0236113.ref045]\] and Parkinson's \[[@pone.0236113.ref046]\].

The aim of this study was to explore the use of intranasal delivery as a potential route to administer THs to palliate the hypothyroid conditions of MCT8-deficient mice by promoting TH signaling in brain without worsening the peripheral hyperthyroidism. We found that, under the present formulation, intranasal administration of THs does not increase the content of THs in the brain and further raise the peripheral TH levels demonstrating that this is not a suitable therapeutic strategy for MCT8 deficiency. Alternative formulations, such as lipid emulsions or lipid nanoemulsions could be considered in the future to improve the nose-to-brain transport.

Materials and methods {#sec002}
=====================

Experimental animals {#sec003}
--------------------

All experimental procedures involving animals were performed following the European Union Council guidelines (directive 2010/63/UE) and Spanish regulations (R.D. 53/2013), and were approved by the ethics committee Comité de Ética y Experimentacion Humana y Animal (CEEHA) at Consejo Superior de Investigaciones Científicas (CSIC) and by the Comunidad Autónoma de Madrid Review Board (proex 162/17) for the use of animals for scientific purposes. The present study was designed following the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines \[[@pone.0236113.ref047]\].

Mice were housed at the Instituto de Investigaciones Biomédicas "Alberto Sols" under temperature- and light-controlled conditions at 22°C on a 12:12 light--dark cycle (lights on at 7.00 am) with food and water *ad libitum*. Animals were housed in groups and were provided with environmental enrichment that included bedding and nesting material. Experiments were performed in Wild type (Wt), MCT8-deficient (*Mct8*KO) and double MCT8- and DIO2-deficient (*Mct8/Dio2*KO) mice at 3 months of age. Only males were used as MCT8 deficiency symptoms manifest in the hemizygous state. Wt and *Mct8*KO mice were originally generated by Dumitrescu and colleagues \[[@pone.0236113.ref022]\] and *Dio2*KO mice by Schneider and colleagues \[[@pone.0236113.ref048]\] in C57BL/6J genetic background and a colony was created at our animal facility in the same strain. The breeding strategy consisted on backcrossing *Mct8*^−/+^ females with *Mct8*^+/y^ males to produce Wt and *Mct8*KO littermates, and *Mct8*^+/y^ *Dio2*^−/−^ males and *Mct8*^−/+^ *Dio2*^−/−^ females to obtain *Mct8/Dio2*KO mice. The *Mct8* and *Dio2* genotypes were confirmed by PCR of tail DNA as described \[[@pone.0236113.ref049]\].

Drug formulations {#sec004}
-----------------

Drugs were prepared at concentrations suitable for intranasal administration. Since only 0.01--1% of an intranasally-administered drug is likely to reach the brain, a highly concentrated dosing solutions were used. L-T3 (Sigma, T6397) and L-T4 (Sigma, T2376) were dissolved in NaOH 0.04 N at 17.14 mg/ml and 24 mg/ml, respectively, and were further diluted into L-T3 0.214 mg/ml and L-T4 0.3 mg/ml in 0.9% NaCl (saline) on the day of the assay to a final pH = 8.

Intranasal treatment {#sec005}
--------------------

For intranasal administration mice where anaesthetized with isoflurane (4% for induction, 2% for maintenance in O2, Abbot Laboratories, Madrid, Spain). After induction, the animals were placed lying on their back and maintaining the head positioned in a way that prevents drainage of the dose solution into the trachea and oesophagus. Eight 3-μl drops of the different TH solutions were administered intranasally every 2 minutes to alternating nares (a total of 24 μl).

Several treatments were performed. First, mice were treated either with saline or with a solution of 0.3 mg/ml L-T4 in saline: Wt + saline n = 3; Wt + T4 n = 3; *Mct8*KO + saline n = 2 and *Mct8*KO + T4 n = 5. In another experiment, mice were treated with saline or with a solution of 0.214 mg/ml L-T3 in saline: Wt + saline n = 7; Wt + T3 n = 7; *Mct8/Dio2*KO + saline n = 8 and *Mct8/Dio2*KO + T3 n = 8. Finally, L-T3 (0.214 mg/ml in saline) was intranasally-administered alone, bound to 1% bovine serum albumin (BSA) or bound to 1% BSA in the presence 1% of the vasoconstrictor phenylephrine hydrochloride (PHE; Sigma, P6126) to Wt animals: Wt + saline n = 11; Wt + T3 n = 11; Wt + T3-1% BSA n = 7 and Wt+T3-1% BSA-1% PHE n = 7. All animals were euthanized by transcardial perfusion under anesthesia 15 minutes after the last administration, as drug uptake in the cerebral cortex has been detected 5 minutes following intranasal administration \[[@pone.0236113.ref050]\]. Mice were anesthetized with ketamine (75 μg/g of BW) and medetomidine hydrochloride (1 μg/g of BW) and a sample of blood was extracted by retroorbital collection to be used for determination of T4 and T3 levels in plasma. Mice were then transcardially perfused with saline to remove blood from tissues and the cerebral hemi-cortices were collected for T4 and T3 determinations. In every case, individual mice were treated as the experimental unit.

BSA-T3 binding assay {#sec006}
--------------------

In order to evaluate the lowest concentration of BSA necessary to bind a solution of 0.214 mg/ml of L-T3, a BSA-T3 binding assay was performed. The ability of BSA to bind a L-T3 replacement dose of 0.020 mg/ml \[[@pone.0236113.ref051]\] was also assessed as a binding control.

Both L-T3 solutions were incubated for 20 minutes at room temperature (RT) with 18,000 cpm of ^125^I-T3 and in presence of different concentrations of BSA: 0.25%, 0.5%, 1%, 1.5%, 2% and 5%. Prior to incubation ^125^I-T3 was purified by removing contaminating iodide by electrophoresis. After incubation, samples were precipitated with 10% trichloroacetic acid by centrifuging 30 minutes at 2,800 rpm and the supernatants were removed. The ^125^I-T3 bound to BSA precipitated was assessed by measuring the ^125^I in a gamma counter detector. Percentage of binding was calculated by referring these measurements to standard samples solely containing the 18,000 cpm of ^125^I-T3.

Radioimmunoassays for T4 and T3 determinations in plasma and tissues {#sec007}
--------------------------------------------------------------------

High specific activity ^125^I-T3 and ^125^I-T4 (3000 μCi/μg) were prepared by labelled with ^125^I (Perkin Elmer, NEZ033A) (3--5)-T2 (Sigma, D0629) and L-T3 (Sigma, T2877), respectively. This was done according to Morreale de Escobar and colleagues \[[@pone.0236113.ref052]\] with the only difference that the separation of the radiolabelled products was performed by ascending paper chromatography in Butanol:Ethanol:Ammonia 0.5N (5:1:2) for 16 h. ^125^I-T3 and ^125^I-T4 were eluted in ethanol and kept at 4°C.

T3 and T4 were extracted as described \[[@pone.0236113.ref052]\]. In short, T3 and T4 were extracted from 80 μl of plasma samples with methanol (1:6), then evaporated to dryness and resuspended in the radioimmunoassay (RIA) buffer. In the hemi-cortices, T3 and T4 were extracted by using methanol-chloroform, back-extracted into an aqueous phase with 0.05% CaCl~2~, and purified and eluted in 70% acetic acid using DOWEX AG 1-X2 columns (Bio Rad, 140--1251). Recoveries of extracted T3 and T4 were calculated by adding tracer amounts of ^125^I-T3, ^125^I-T4 to the initial homogenates. The purified extracts were used for T3 and T4 determinations by sensitive RIAs as previously described \[[@pone.0236113.ref052]\] with a range of 0.4--50 pg T3/tube and 2.5--320 pg T4/tube and for both RIAs a 5% coefficient for intra-assay variation and a 10--15% coefficient for inter-assay variation.

Statistics {#sec008}
----------

Data are expressed as box and whisker plots with individual values. Chi-Square tests were performed to detect outliers, which were excluded from further analyses. Differences between means were obtained either by two-way analysis of variance (ANOVA) and Bonferroni's post hoc test to correct for multiple comparisons between groups that are split on two independent variables (with treatment and genotype as factors) or with one-way ANOVA and the Bonferroni's post hoc test to correct for multiple comparisons between unrelated groups. Significant differences are represented as \*p\<0.0332, \*\*p\<0.0021, \*\*\*p\<0.0002 and \*\*\*\*p\<0.0001. All analyses were performed using GraphPad Prism 8.

Results {#sec009}
=======

Intranasal treatment with T4 increases plasma T4 levels {#sec010}
-------------------------------------------------------

We did a pilot study to determine if THs significantly entered the blood following intranasal delivery, as this would complicate the assessment of direct nose-to-brain delivery. Treatment with T4 was chosen over that with T3, as T4 is the primary source of T3 in the brain and DIO2 activity can locally modulate the conversion of T4 into T3 to make it available to the appropriate target neural cells. For this reason, the MCT8-deficient animal model chosen for this set of experiments was *Mct8*KO mice, that has an elevated DIO2 activity in the brain \[[@pone.0236113.ref022], [@pone.0236113.ref023]\].

In order to assess the ability of T4 to reach the blood following intranasal administration, Wt and *Mct8*KO counterparts were treated intranasally with either saline or T4, and 15 minutes later, plasma samples were collected to assess the concentrations of T4. Intranasal treatment with T4 greatly increased plasma T4 levels in the following 15 minutes after delivery both in Wt (3.5-fold) and *Mct8*KO mice (5-fold; [Fig 1](#pone.0236113.g001){ref-type="fig"}) compared to controls given saline ([Fig 1](#pone.0236113.g001){ref-type="fig"}).

![Thyroxine (T4) levels in plasma of wild type (Wt) and MCT8 knockout (*Mct8*KO) mice 15 minutes after intranasal treatment with saline or L-T4.\
Data are presented as box and whisker plots with individual values, showing median (horizontal line), boxes representing the 25th to 75th percentiles and whiskers representing the minimum and maximum values. P values \*p\<0.0332 and \*\*\*\*p\<0.0001 were determined by two-way analysis of variance (ANOVA) and Bonferroni's post hoc test, the two factors being genotype and treatment. Significant differences with the saline-treated Wt group are indicated on top of each column, while significant differences between the remaining groups are indicated with lines.](pone.0236113.g001){#pone.0236113.g001}

Because T4 levels increase in plasma after intranasal delivery, and as mice abundantly present the T4 transporter OATP1C1 at the BBB, it would have not been possible to determine if a potential increase in T4 content in the cerebral cortex could be mediated by direct nose-to-brain transport or indirect access of T4 from the blood to the brain. In the direct nose-to-brain route, T4 administered transnasally would travel through extracellular pathways described for intranasal delivery from the nasal cavity to the brain. Alternatively, T4 accessing the blood stream following intranasal delivery could be being transported indirectly into the brain by crossing the BBB through the OATP1C1 transporter.

In view of the results obtained after intranasal administration of T4 to Wt and *Mct8*KO mice, it was essential 1) to establish if THs delivered intranasally can directly access the brain by nose-to-brain transport and 2) to reduce the amount of THs administered intranasally reaching the plasma in order to avoid worsening the peripheral hyperthyroidism characteristic of MCT8-deficient patients.

Intranasal T3 treatment does not increase brain T3 content and further elevates plasma T3 levels {#sec011}
------------------------------------------------------------------------------------------------

To determine if intranasal administration of THs can directly access the brain, we decided to execute an intranasal treatment with L-T3, which does not cross the BBB through OATP1C1, in double *Mct8/Dio2*KO mice, which present further reduced T3 content in the brain in comparison to single *Mct8*KO mice \[[@pone.0236113.ref053], [@pone.0236113.ref054]\] and therefore present higher sensitivity to detect increases in T3 brain content. For this, Wt and *Mct8/Dio2*KO mice were treated with either saline or L-T3 by intranasal administration and plasma and cerebral cortex samples were collected 15 minutes after for TH determinations.

In the saline-treated group, T3 and T4 levels in plasma reflected the characteristic thyroid function test in MCT8 deficiency with high T3 (3-fold increase) and low T4 (1.6-fold decrease) in *Mct8/Dio2*KO animals in comparison to Wt ([Fig 2](#pone.0236113.g002){ref-type="fig"}) \[[@pone.0236113.ref022], [@pone.0236113.ref023]\]. In the cerebral cortex, *Mct8/Dio2*KO mice displayed a 5-fold decrease in T3 content and a 1.6-fold decrease in T4 content, as previously described ([Fig 2](#pone.0236113.g002){ref-type="fig"}) \[[@pone.0236113.ref053], [@pone.0236113.ref054]\].

![T4 and 3,5,3'-triiodothyronine (T3) levels/content in plasma and cerebral cortex of Wt and MCT8 and DIO2 knockout (*Mct8/Dio2*KO) mice 15 minutes after intranasal treatment with saline or L-T3.\
Data are presented as box and whisker plots with individual values, showing median (horizontal line), boxes representing the 25th to 75th percentiles and whiskers representing the minimum and maximum values. P values \*p\<0.0332, \*\*p\<0.0021, \*\*\*p\<0.0002 and \*\*\*\*p\<0.0001 were determined by two-way ANOVA and Bonferroni's post hoc test, the two factors being genotype and treatment. Significant differences with the saline-treated Wt group are indicated on top of each column, while significant differences between the remaining groups are indicated with lines.](pone.0236113.g002){#pone.0236113.g002}

After intranasal treatment with L-T3, T4 levels in plasma and T4 content in the cerebral cortex were not affected either in Wt or in *Mct8/Dio2*KO mice. However, this treatment increased by 4-fold the plasma T3 levels in Wt animals and by 3-fold in *Mct8/Dio2*KO mice ([Fig 2](#pone.0236113.g002){ref-type="fig"}). In the cerebral cortex, intranasal treatment with L-T3 did not increase T3 content in *Mct8/Dio2*KO animals. However, in Wt animals there was a 1.3-fold increase in the content of T3 after intranasal L-T3 treatment, likely due to the presence of MCT8 at the BBs that can transport the increased levels of T3 in plasma to the brain.

The use of carrier proteins or vasoconstrictors does not prevent T3 from reaching the blood {#sec012}
-------------------------------------------------------------------------------------------

In order to inhibit THs from reaching the bloodstream following intranasal administration, the possibility of using carriers both suitable for intranasal administration and capable of binding THs was evaluated. A suitable potential carrier for TH intranasal administration is bovine serum albumin (BSA). Previous studies have demonstrated that BSA delivered intranasally is able to distribute throughout the mouse brain shortly after administration, with minimal penetration to the systemic circulation \[[@pone.0236113.ref050]\]. Moreover, BSA binds T3 with a relatively high affinity \[[@pone.0236113.ref055]\]. In view of this, we hypothesized that BSA can be used as a carrier to deliver T3 to the brain by means of intranasal administration reducing access to the bloodstream.

In order to determine the most suitable concentration of BSA that is able to bind a 0.214 mg/ml solution of L-T3, a radioactive T3-BSA binding assay was performed. A T3 replacement dose of 0.020 mg/ml \[[@pone.0236113.ref051]\] was run in parallel as a binding control. Both L-T3 solutions were incubated with a tracer quantity of ^125^I-T3 in presence of different concentrations of BSA: 0.25%, 0.5%, 1%, 1.5%, 2% and 5%. As shown in [Table 1](#pone.0236113.t001){ref-type="table"}, the ability of BSA to bind T3 was similar for both L-T3 solutions. 1% BSA was already binding 84.1% of the highly concentrated T3 and further concentrating BSA up to 5% only increased T3 binding in 6%. As Falcone, Salameh (50) used 1% BSA in their studies assessing the distribution of BSA throughout the brain and plasma after intranasal administration, and taking into account that 1% BSA binds 84.1% of a 0.214 mg/ml L-T3 solution, 1% BSA was considered the most suitable concentration to use as a carrier for intranasal administration of T3.

10.1371/journal.pone.0236113.t001

###### Percentage of 0.214 mg/ml and 0.02 mg/ml solutions of L-T3 bound to 0.25%, 0.5%, 1%, 1.5%, 2% and 5% bovine serum albumin (BSA).

![](pone.0236113.t001){#pone.0236113.t001g}

                     0.25% BSA   0.5% BSA   1% BSA   1.5% BSA   2% BSA   5% BSA
  ------------------ ----------- ---------- -------- ---------- -------- --------
  0.214 mg/ml L-T3   70.5%       79.7%      84.1%    87.8%      88.06%   90%
  0.020 mg/ml L-T3   ND          79.9%      88.8%    ND         94.7%    97.2%

ND = not determined.

Other strategies that improve the delivery of drugs into the brain after intranasal administration yet decreasing the amount of drug absorbed into the systemic circulation consist on the use of vasoconstrictors. In particular, the vasoconstrictor phenylephrine (PHE) has been successfully used to increase the brain-to-plasma ratio \[[@pone.0236113.ref056]\].

Taking into account all the above, animals were treated either with L-T3, with L-T3 bound to 1% BSA or with L-T3 bound to 1% BSA and PHE 1%. As the aim of this experiment was to evaluate the capacity of BSA and PHE to prevent L-T3 from reaching the blood after intranasal administration, these treatments were performed only in Wt mice. Fifteen minutes after treatment, blood samples were collected to assess plasma T3 levels. T3 determinations in plasma revealed that, as expected, intranasal treatment with L-T3 reached the circulation and increased plasma T3 levels by 8.5-fold in comparison to untreated basal levels. Intranasal delivery of L-T3 bound to 1% BSA either in the absence or presence of the vasoconstrictor PHE was not able to prevent T3 from reaching the circulation as both treatments increased T3 levels in plasma more than 10-fold in comparison to untreated values ([Fig 3](#pone.0236113.g003){ref-type="fig"}).

![T3 levels in plasma of Wt mice 15 minutes after intranasal treatment with L-T3, L- T3 bound to 1% bovine serum albumin (T3-BSA) or L-T3 bound to 1% BSA in the presence of 1% vasoconstrictor phenylephrine hydrochloride (T3-BSA-PHE).\
Data are presented as box and whisker plots with individual values, showing median (horizontal line), boxes representing the 25th to 75th percentiles and whiskers representing the minimum and maximum values. P values \*\*\*\*p\<0.0001 was determined by one-way ANOVA and Bonferroni's post hoc test. Significant differences with the saline-treated Wt group are indicated on top of each column.](pone.0236113.g003){#pone.0236113.g003}

Discussion {#sec013}
==========

Patients with inactivating mutations in the TH transporter MCT8 suffer from peripheral hyperthyroidism and brain hypothyroidism. The state of brain hypothyroidism leads to severe neuropsychomotor abnormalities in all probability due to impaired transport of THs to the brain. No postnatal therapeutic strategies attempted so far have been able to improve the neurological defects. Since these alterations arise in part due to impaired TH transport across the BBs, a drug administration route that bypasses the BBs has the potential to deliver THs to the brain in the absence of MCT8. However, whether administration of THs to the brain during postnatal stages can revert the neurological impairments that have already taken place during early brain development \[[@pone.0236113.ref024]\] is an unresolved question. Some of the delivery routes that have the potential to circumvent the BBs include the intracerebroventricular and the intranasal administration pathways. Although both administration routes are routinely used for different treatments in humans, if successful, intranasal delivery presents certain advantages over intracerebroventricular administration, as the former is less invasive. In the present study, we aimed to evaluate the intranasal administration route as a pathway to deliver THs directly into brain in the absence of MCT8.

As T4 is the primary source of T3 in the brain, we treated *Mct8*KO mice with a 0.3 mg/ml solution of T4 by intranasal administration that led to increased plasma T4 levels. However, as *Mct8*KO present the T4 transporter OATP1C1 at the BBs, a potential T4 increase in the brain could be mediated by the transport of T4 from the blood to the brain through the BBB. In order to establish whether intranasal administration of THs can reach the brain by nose-to-brain transport, we treated *Mct8/Dio2*KO mice with a solution of 0.214 mg/ml L-T3, as the OATP1C1 transporter is not involved in T3 transport to the brain in mice \[[@pone.0236113.ref025]\]. Intranasal L-T3 administration further elevated plasma T3 levels in Wt and *Mct8/Dio2*KO mice and, most importantly, T3 content in the cerebral cortex of *Mct8/Dio2*KO animals did not increase after treatment while it did so in Wt animals. This can be explained by T3 transport from the plasma to the brain through the MCT8 transporter in Wt animals, especially since plasma T3 levels were elevated after treatment. It can be therefore concluded that intranasal treatment with THs in mice does not increase TH content in the brain and further increases plasma TH levels, aggravating the peripheral hyperthyroidism. It has been postulated that about 0.01 to 1% of a given drug reaches the brain after intranasal administration \[[@pone.0236113.ref057]\]. Based on this, considering that a total of 5 μg were delivered in the present study and taking into account the brain T3 content in basal conditions in each genotype ([Fig 2](#pone.0236113.g002){ref-type="fig"}), we estimate that this would have represented a- 1.25- to 25-fold increase in T3 brain content in a Wt animal and a 2- to 100-fold increase in T3 brain content in a *Mct8/Dio2*KO mouse. Therefore, an unsuitable dose of L-T3 is not likely to explain the lack of increase in T3 content after nasal treatment.

An additional potential drawback for intranasal TH treatment in MCT8-deficient patients identified in this study is the increase in the TH plasma levels following delivery. This would potentially worsen the peripheral hyperthyroidism with detrimental effects. There are some approaches that increase the brain-to-blood ratio and therefore reduce or even prevent the administered drug from reaching the blood. These include the use of carrier proteins and vasoconstrictors such as BSA and PHE, respectively. In previous studies, BSA reached the frontal, parietal and occipital cortex as early as 5 minutes and up to 4 hours after nasal delivery, and only 2--4% entered the systemic circulation \[[@pone.0236113.ref050]\]. Moreover, the vasoconstrictor PHE has been proven to reduce absorption of certain peptides into the blood by 65% after intranasal administration \[[@pone.0236113.ref056]\]. Based on these findings we treated Wt mice with L-T3, L-T3 bound to 1% BSA and L-T3 bound to 1% BSA in the presence of 1% PHE aiming to reduce the amount of T3 entering the systemic circulation. Unfortunately, neither of these treatments was successful in reducing or preventing T3 from reaching the bloodstream.

In the present study, there was a 1.18 ± 0.14 ng/ml increase in the plasma levels of T3 in Wt animals. Assuming a 1:1 ratio of blood cells to plasma \[[@pone.0236113.ref058]\], we estimate that 0.035% of the administered L-T3 entered the systemic circulation. We cannot explain why the use of BSA as a carrier protein and the vasoconstrictor PHE was not able to reduce the amount of T3 reaching the bloodstream. The reason why some drugs reach the systemic circulation after intranasal delivery while others do not, is not fully understood \[[@pone.0236113.ref059]\]. It has been proposed that lipid soluble molecules can be rapidly absorbed from the nasal membrane into the bloodstream with a bioavailability of over 75%, while this percentage decreases to 10% for small, polar molecules and to less than 1% for large peptide molecules \[[@pone.0236113.ref060]\]. Despite the lipophilic nature of THs, it is very unlikely that these are being absorbed from the nasal epithelium to the blood after intranasal administration, as it has been established that THs need transporter proteins to cross cellular membranes \[[@pone.0236113.ref010]\]. Alternatively, THs could be being transported from the nasal epithelium to the blood by transporter proteins. In fact, the OATP3 transporter (encoded by *SLC21A7* and involved in TH transport) has been detected at remarkably high levels at the olfactory and nasal epithelia \[[@pone.0236113.ref061]\]. The presence of this transporter at the olfactory epithelium could be mediating a rapid transport of THs from the nose to blood, thus preventing THs from reaching the brain. Moreover, a quick degradation of THs at the nasal mucosa by DIO3 \[[@pone.0236113.ref062]\], that converts T4 and T3 into inactive metabolites, could also be responsible for the lack of TH increase in the brain. Due to the hydrophobic nature of THs and the solution used in this study, is it important to consider that THs could have precipitated in the nasal epithelium upon delivery. The possibility of using a lipid microemulsion formulation to intranasally administer TH to the brain could be considered for future approaches, as this has already been successfully used to deliver Growth differentiation factor 5, a water insoluble protein, to the brain \[[@pone.0236113.ref063]\].

Altogether, the findings of the present work indicate that the administration of THs by intranasal delivery is not suitable for the treatment of MCT8 deficiency, as this delivery route does not facilitate direct nose-to-brain transport of THs that would potentially ameliorate the brain hypothyroidism. Furthermore, this treatment increases TH plasma levels that would further aggravate peripheral hyperthyroidism characteristic of MCT8-deficient patients. However, our inability to formulate T3 and T4 in such a way as to successfully intranasally deliver and target them to the brain should not deter others from doing so, perhaps using a lipid emulsion or lipid nanoparticle formulation \[[@pone.0236113.ref064]\].
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Dear Dr. Guadaño-Ferraz,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Consequently, after considering the commentaries made by three reviewers, Major Revision is requested.

It is worth mentioning that such a decision is justified by taking into account the concerns raised by the reviewers regarding the statistical approach, as well as the publication requirements for PLOS ONE regarding that the papers must be technically sound and the data should support the conclusions.

Accordingly, please carefully address the issues raised in the comments provided by the reviewers appended below, which can help to improve and strengthen your submission.

Please submit your revised manuscript by Jul 27 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Maria Carmen Iglesias-Osma, M.D., Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. At this time, we request that you  please report additional details in your Methods section regarding animal care, as per our editorial guidelines:

\(1\) Please state whether the provided ethics committee contains animal welfare experts or whether an animal ethics or IACUC committee reviewed and approved the study. Please provide the full name of the committee that reviewed and approved the study  

\(2\) Please include the method of euthanasia  

\(3\) Please provide the source of the animals used in the study.

Thank you for your attention to these requests.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript reports a study of the effectiveness of intranasal delivery of thyroid hormone in the treatment of monocarboxylate transporter 8 (MCT8) deficiency. Loss of function mutations in MCT8 in humans lead to severe neurodevelopmental defects, apparently due to impairment in the transport of thyroid hormone across the blood brain barrier. Although these mutations result in hypothyroidism in the brain they produce hyperthyroidism in peripheral tissues. This manuscript describes a test of the ability of intranasal delivery of thyroid hormone as a means to bypass the brain blood barrier and selectively correct the hypothyroid neurological phenotype.

The authors tested intranasal delivery of T4 or T3 thyroid hormone in WT, MCT8 deficient, and double MCT8-/DIO2 deficient mice. Although the intranasal route greatly increased plasma T3 or T4 levels compared to controls, no, or only statistically non-significant increases in hormone in cerebral cortex in the MCT8 deficient animals were detected. Given the further increases in plasma thyroid hormone levels observed with intranasal administration were non-desirous, the authors also tested hormone formulations containing BSA (which binds T3 and T4) with or without phenylephrine (PHE) a vasoconstrictor. Neither formulation diminished the rise in serum thyroid hormone observed after intranasal administration. The authors conclude that their "data suggests intranasal delivery of thyroid hormones is not a suitable therapeutic strategy for MCT8 deficiency, although alternative formulations could be considered in the future to improve the nose-to-brain transport."

The experiments described here appear to be well designed and carefully performed. Appropriate controls were employed, a variety of approaches were tested, the results are definitive, and the authors' conclusions are convincing. Given that MCT8 deficiency in humans creates severe neurodevelopmental defects, the clinical need for exploring methods to ameliorate this defect is clear. Further, the authors' approach to this goal was logical: intranasal delivery has been demonstrated previously as a non-invasive route that can, for several drugs, bypass the blood brain barrier. Although the ultimate results reported here were negative, i.e. that the intranasal route was not successful, this study is nonetheless valuable both for demonstrating that the intranasal approach as formulated here is not effective (important information for other scientists who might otherwise be tempted to try the same approach) and as a foundation for future approaches that may prove more useful. Very few specific concerns were noted:

1\. All studies here assayed cerebral cortex levels of T3 or T4 thyroid hormone 15 minutes after administration. Why did the authors choose 15 mins. and has a more extensive time course been examined?

2\. An interesting question is if counteracting the brain hypothyroidism in adults is likely to substantially ameliorate (at least in part) the neurological defects, or if the MCT8 defect may already have produced irreparable damage by the fetus/neonate stages. The authors should include a discussion of this issue.

3\. The authors may wish to consider presenting their data as box-whisker plots, which would better visualize the statistics involved, rather than as columns; however this is not a requirement.

Reviewer \#2: In the present manuscript, Grijota-Martínez et al. attempt to intranasally deliver thyroid hormones to the CNS to potentially treat centrally induced deficiencies associated with MCT8. My major concern is with the authors\' conclusion that they are not able to increase thyroid hormones in the brain through the intranasal route. It seems that the experiments were not sufficiently powered to draw this conclusion. Data generated from the intranasal route is typically more variable than data generated by other routes of administration. The conclusion that intranasal administration of T4 does not increase brain levels based on an n=2 or 3 at a single 15 minute time point is not convincing. Two or three animals per treatment group is rarely sufficient to draw a statistically significant conclusion, especially with the intranasal route. The data shows a trend towards increased T4 in cortex after intranasal administration. This increase would likely be statistically significant if the study was not so underpowered. An n=6 animals per treatment group for the studies described in Figure 1 would be much more convincing. There is simply not enough data currently in the manuscript to conclude that intranasal delivery of thyroid hormones does not result in delivery to the CNS.

Reviewer \#3: In this manuscript the authors describe studies where T4 and T3 were administered intranasally to mouse models lacking the thyroid hormone transporter MCT8 to determine if this could be an effective strategy to increase thyroid hormone (TH) levels in the brain. They also assessed and if this led to changes in circulating TH, and evaluated other strategies such as binding T3 with BSA or use of the vasoconstrictor phenylephrine to prevent TH spillover into the circulation. This study has important clinical applications since patients with MCT8 mutations have impaired TH transport across the blood brain barrier which leads to severe and devastating neurological impairment. Although the authors do not find that any of the protocols described are an effective strategy to alter TH levels in either of the MCT8KO models used, they present a strong starting point towards future studies which could lead to important therapies. These studies are clearly presented and the introduction and discussion are well written, informative, and balanced with the limitations considered and acknowledged.

1\. In the discussion the authors elaborate on the rationale behind the dosages used but can they also discuss why they chose the timing that was used? Have they looked at TH content (or also possibly expression of TH-regulated genes) in the brain at later time points after administration?

2\. In Fig. 2. why is the student's t-test between saline treated WT and Mct8/Dio2KO also added in? The two-way ANOVA plus Bonferroni's post test is more appropriate.

3\. While these strategies may not have prevented spillover into the circulation they still may have facilitated uptake into the brain. Do the authors have any data in this regard?

4\. Minor point: Figure 3 doesn't have statistical differences indicated.

5\. Lines 354-358. I don't follow the logic of this section. If 0.01% to 1% of 5 micrograms of T3 was estimated to be delivered wouldn't 0.5 to 50 ng to be delivered to both genotypes? Why are the estimated increases different between Wt and Mct8/Dio2KO? Please clarify.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Dr. Guadaño-Ferraz,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Maria Carmen Iglesias-Osma, M.D., Ph.D.

Academic Editor

PLOS ONE
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Dear Dr. Guadaño-Ferraz:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Dr. Maria Carmen Iglesias-Osma

Academic Editor

PLOS ONE
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